查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586189

细胞健康筛检市场：按测试类型、样本类型划分 - 2025-2030 年全球预测

Cellular Health Screening Market by Test Type (Heavy Metal Tests, Inflammation Tests, Multi-Test Panels), Sample Type (Blood, Body Fluids) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞健康筛检市场2023年估值为31亿美元，预计2024年将达34.7亿美元，复合年增长率为11.75%，预计到2030年将达到67.7亿美元。

细胞健康筛检包括评估细胞生物标记物，以评估整体健康状况和潜在疾病风险。这个领域由测量细胞老化、氧化压力和粒线体健康的技术定义，对于预防性医疗保健和个人化医疗至关重要。细胞健康筛检的需求源自于全球健康意识的提高以及慢性病管理中对早期检测工具的需求。细胞健康筛检的应用超越了临床用途（包括健康中心和个人用途），可以为各种最终用户（包括医疗保健提供者、研究人员和健身专业人员）提供服务。市场成长受到生物标记检测技术进步和个人化医疗解决方案投资增加的显着影响。随着人口老化，对非侵入性诊断工具的需求显着增加，为相关人员创造了利润丰厚的机会。然而，高成本、监管复杂、测试结果缺乏标准化等挑战正在限制市场。儘管存在这些障碍，但持续的创新（例如整合人工智慧以获得准确结果以及开发便携式且经济高效的设备）提供了有希望的成长轨迹。公司可以利用这些机会，专注于遵守不断变化的监管标准，同时投资研发以提高测试准确性并降低成本。扩大教育和宣传工作以提高消费者对细胞健康筛检益处的认识也至关重要。市场的本质是动态的，其特点是技术快速进步和消费者对个人化健康解决方案的需求不断增长。基因组学和奈米技术等领域的创新有可能进一步改变这一领域，并促进早期疾病检测和健康监测的进步。追求长期成长的公司应优先考虑适应这些技术趋势并培养策略伙伴关係关係，以扩大市场覆盖范围和竞争力。透过克服现有挑战并拥抱创新，公司可以显着影响细胞健康筛检、推动市场扩张并改善人类健康结果。

主要市场统计
基准年[2023] 31亿美元
预测年份 [2024] 34.7亿美元
预测年份 [2030] 67.7亿美元
复合年增长率（%） 11.75%

市场动态：快速发展的细胞健康筛检市场的关键市场洞察

供需的动态交互作用正在改变细胞健康筛检市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 乳癌和摄护腺癌筛检可以显着降低个人的死亡风险。
    • 慢性病造成的经济负担日益加重
    • 更多采用端粒功能程序
  • 市场限制因素
    • 过度诊断是筛检中不可避免的一部分，会对人们造成有害后果，例如心理困扰和失禁。
  • 市场机会
    • 活性化研究活动并快速采用直接接触客户的方法
    • 政府对预防性医疗保健的兴趣日益浓厚
  • 市场挑战
    • 一些经济体检费用上升和资源短缺

波特五力：驾驭细胞健康筛检市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解细胞健康筛检市场的外部影响

外部宏观环境因素在塑造细胞健康筛检市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细胞健康筛检市场的竞争格局

细胞健康筛检市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵细胞健康筛检市场供应商的绩效评估

FPNV定位矩阵是评估细胞健康筛检市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製细胞健康筛检市场的成就之路

对于旨在加强在全球市场的影响力的公司来说，细胞健康筛检市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 乳癌和摄护腺癌筛检可以显着降低个人的死亡风险。
      • 慢性病造成的经济负担增加
      • 更多采用端粒性能计划
    • 抑制因素
      • 过度诊断是筛检的必要条件，会对人们造成有害后果，例如心理困扰和失禁。
    • 机会
      • 研究活动迅速增加并采用直接面对客户的方法
      • 政府对预防性医疗保健的兴趣日益浓厚
    • 任务
      • 一些经济体测试成本高且资源稀缺
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按测试类型分類的细胞健康筛检市场

  • 重金属测试
  • 发炎测试
  • 多测试板
  • 氧化压力测试
  • 端粒测试

第七章依样本类型分類的细胞健康筛检市场

  • 血
  • 体液

第八章美洲细胞健康筛检市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太细胞健康筛检市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲细胞健康筛检市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Cell Science Systems Corporation
  • Cell Signaling Technology, Inc.
  • Danaher Corp
  • Laboratory Corporation of America Holdings
  • Life Length SL
  • LifeVault Bio, Inc
  • Merck KGaA
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • Quest Diagnostics
  • Repeat Diagnostics, Inc.
  • SpectraCell Laboratories Inc
  • Thermo Fisher Scientific Inc.
  • Viome Life Sciences, Inc.
Product Code: MRR-433AB1DC28DE

The Cellular Health Screening Market was valued at USD 3.10 billion in 2023, expected to reach USD 3.47 billion in 2024, and is projected to grow at a CAGR of 11.75%, to USD 6.77 billion by 2030.

Cellular health screening encompasses the evaluation of cellular biomarkers to assess overall health status and potential disease risks. This field is defined by techniques measuring cellular aging, oxidative stress, and mitochondrial health, crucial for preventive healthcare and personalized medicine. The necessity of cellular health screening arises from the increasing global health awareness and demand for early detection tools in chronic disease management. Its applications extend beyond clinical settings, including wellness centers and individual use, serving diverse end-users like healthcare providers, researchers, and fitness professionals. The market growth is significantly influenced by technological advancements in biomarker detection and increasing investment in personalized healthcare solutions. As the aging population grows, there's a substantial rise in demand for non-invasive diagnostic tools, presenting lucrative opportunities for stakeholders. However, challenges such as high costs, regulatory complexities, and a lack of standardization in test results pose significant market restraints. Despite these hurdles, ongoing innovations like artificial intelligence integration for precise results and developing portable, cost-effective devices offer promising growth trajectories. Companies can capitalize on these opportunities by investing in research and development to improve test accuracy and reduce costs, while also focusing on compliance with evolving regulatory standards. Expanding educational outreach to increase consumer awareness about the benefits of cellular health screening is also crucial. The market's nature is dynamic, characterized by rapid technological progress and increasing consumer demand for personalized health solutions. Innovation in areas like genomics and nanotechnology could further revolutionize this field, facilitating advancements in early disease detection and health monitoring. Companies aiming for long-term growth should prioritize adapting to these technological trends and fostering strategic partnerships to enhance market reach and competitiveness. By navigating existing challenges and embracing innovation, businesses can significantly impact cellular health screening, driving market expansion and improving population health outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 3.10 billion
Estimated Year [2024] USD 3.47 billion
Forecast Year [2030] USD 6.77 billion
CAGR (%) 11.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cellular Health Screening Market

The Cellular Health Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Screening for breast and prostate cancer can significantly reduce an individual's risk of dying
    • Increasing economic burden of chronic diseases
    • Increasing adoption of telomere performance programs
  • Market Restraints
    • Overdiagnosis is inevitability of screening leading to harmful consequences for people, including psychological distress, and incontinence
  • Market Opportunities
    • Rise in research activities, and a rapidly growing adoption of direct to customer approach
    • Rising government focus towards preventive healthcare
  • Market Challenges
    • High costs of screening and lack of resources in some economies

Porter's Five Forces: A Strategic Tool for Navigating the Cellular Health Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cellular Health Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cellular Health Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cellular Health Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cellular Health Screening Market

A detailed market share analysis in the Cellular Health Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cellular Health Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cellular Health Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cellular Health Screening Market

A strategic analysis of the Cellular Health Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cellular Health Screening Market, highlighting leading vendors and their innovative profiles. These include Cell Science Systems Corporation, Cell Signaling Technology, Inc., Danaher Corp, Laboratory Corporation of America Holdings, Life Length S.L., LifeVault Bio, Inc, Merck KGaA, OPKO Health, Inc., PerkinElmer Inc., Quest Diagnostics, Repeat Diagnostics, Inc., SpectraCell Laboratories Inc, Thermo Fisher Scientific Inc., and Viome Life Sciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Cellular Health Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Heavy Metal Tests, Inflammation Tests, Multi-Test Panels, Oxidative Stress Tests, and Telomere Tests.
  • Based on Sample Type, market is studied across Blood and Body Fluids.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Screening for breast and prostate cancer can significantly reduce an individual's risk of dying
      • 5.1.1.2. Increasing economic burden of chronic diseases
      • 5.1.1.3. Increasing adoption of telomere performance programs
    • 5.1.2. Restraints
      • 5.1.2.1. Overdiagnosis is inevitability of screening leading to harmful consequences for people, including psychological distress, and incontinence
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in research activities, and a rapidly growing adoption of direct to customer approach
      • 5.1.3.2. Rising government focus towards preventive healthcare
    • 5.1.4. Challenges
      • 5.1.4.1. High costs of screening and lack of resources in some economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cellular Health Screening Market, by Test Type

  • 6.1. Introduction
  • 6.2. Heavy Metal Tests
  • 6.3. Inflammation Tests
  • 6.4. Multi-Test Panels
  • 6.5. Oxidative Stress Tests
  • 6.6. Telomere Tests

7. Cellular Health Screening Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Blood
  • 7.3. Body Fluids

8. Americas Cellular Health Screening Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cellular Health Screening Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cellular Health Screening Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Cell Science Systems Corporation
  • 2. Cell Signaling Technology, Inc.
  • 3. Danaher Corp
  • 4. Laboratory Corporation of America Holdings
  • 5. Life Length S.L.
  • 6. LifeVault Bio, Inc
  • 7. Merck KGaA
  • 8. OPKO Health, Inc.
  • 9. PerkinElmer Inc.
  • 10. Quest Diagnostics
  • 11. Repeat Diagnostics, Inc.
  • 12. SpectraCell Laboratories Inc
  • 13. Thermo Fisher Scientific Inc.
  • 14. Viome Life Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. CELLULAR HEALTH SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. CELLULAR HEALTH SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CELLULAR HEALTH SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CELLULAR HEALTH SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CELLULAR HEALTH SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CELLULAR HEALTH SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELLULAR HEALTH SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELLULAR HEALTH SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY HEAVY METAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY INFLAMMATION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY MULTI-TEST PANELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY OXIDATIVE STRESS TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY TELOMERE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELLULAR HEALTH SCREENING MARKET SIZE, BY BODY FLUIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES CELLULAR HEALTH SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CELLULAR HEALTH SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM CELLULAR HEALTH SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM CELLULAR HEALTH SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. CELLULAR HEALTH SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. CELLULAR HEALTH SCREENING MARKET, FPNV POSITIONING MATRIX, 2023